Trial Profile

A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (Somavaratan, VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 27 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Oct 2017 Status changed from recruiting to discontinued, according to a Versartis media release.
27 Apr 2017 According to a Versartis media release, the company anticipates to complete enrollment in the phase III portion of the trial in the second half of 2017.
04 Apr 2017 Results (n=48) comapring PK/PD properties of somavaratan in USA and Japan prepubertal children using patient data from VERTICAL and J14VR5 trials, presented at The 99th Annual Meeting of the Endocrine Society

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com